Enlivex Ltd. (ENLV) SEC Filings & Earnings Calls

Reverse split may signal low share price and potential delisting risk, though it can also be a compliance measure.

“reverse share split at a ratio of 1-for-16”

Cash burn reduction plan indicates financial distress; reliance on Phase 2b trial success.

“Plan designed to substantially reduce cash burn; workforce reduction of 60%.”

Reverse stock split may indicate low share price; no other material risk.

“Proposed 1-for-16 reverse share split.”

Loss of planned equity financing; potential liquidity risk if alternative funding not secured.

“Termination of private placement that would have raised capital via RAIN tokens.”

Financial distress: company's market cap fell below $75M triggering default; debt restructuring with higher principal and contingent interest suggests liquidity pressure.

“Event of default due to market cap <$75M for 10 consecutive days; waiver granted; interest accrues at 10% when market cap <$75M.”

Crypto asset volatility: RAIN token price and liquidity are highly volatile; treasury value dependent on prediction market adoption.

“Forward-looking statements highlight highly volatile nature of RAIN and other cryptocurrencies.”

No material risk signals; filing is a routine webinar announcement with no financial results or operational changes.

Shareholder approval required; dilution risk; put option could lead to further dilution.

“Closing subject to shareholder approval; put option for additional $400M shares.”

Shareholder approval required; dilution risk; put option could lead to further dilution if exercised.

“Closing subject to shareholder approval for Nasdaq and Israeli law; put option for additional $400M shares.”

Crypto asset volatility: RAIN token price and liquidity are highly volatile; treasury value subject to market fluctuations.

“Forward-looking statements highlight highly volatile nature of RAIN and other cryptocurrencies.”

Clinical and regulatory risk: RMAT designation does not guarantee approval; Phase IIb trial results and FDA meeting outcomes are uncertain.

“Forward-looking statements caution that RMAT designation does not guarantee faster development or FDA approval.”

Reverse split may indicate low share price pressure and potential delisting risk; no change in fundamentals.

“Reverse split at 1-for-15 ratio; shares trading on Nasdaq Capital Market; no financial data provided.”

Dependence on volatile crypto asset (RAIN) for treasury value; exchange listing does not eliminate price or liquidity risk.

“RAIN token price and liquidity remain highly volatile; treasury NAV per share fluctuates with token price.”

Treasury value highly dependent on volatile RAIN token price; no diversification.

“Treasury NAV per share derived from RAIN token price; token price subject to significant volatility.”

Treasury concentration in single volatile crypto asset; ecosystem developments positive but do not eliminate price risk.

“RAIN token value fluctuates; treasury NAV per share derived from token price.”

Treasury and option value highly dependent on RAIN token price; option expiration Dec 31, 2027 introduces time decay risk.

“Option intrinsic value of $2.23B based on RAIN token price; token price volatility could erode value.”

Clinical trial risk: Phase 2b may fail to meet endpoints; no revenue from Allocetra yet; treasury dependent on RAIN token.

“Phase 2b trial is ongoing; no efficacy or safety data reported; company has no approved products.”

Potential delisting if compliance not regained; reverse split may be necessary but does not address underlying business issues.

“If Company is unable to regain compliance by November 9, 2026, it may be eligible for an additional 180 calendar day compliance period... if not, Nasdaq will notify the Company that its ordinary shares are subject to delisting.”

Clinical trial risk remains; regulatory approval does not guarantee trial success or eventual market approval.

“Phase 2b trial is still in early stages; no efficacy data reported.”

Tokenization may not lead to increased liquidity or investor interest; regulatory and technological risks.

“risk that tokenization of the Company’s equity does not lead to increased liquidity, trading activity, or investor interest; risks associated with digital asset exchanges, custodians, trading venues, and market infrastructure; legal, tax, commercial, and regulatory uncertainty regarding tokenized securities and digital assets” · word for word

Risks related to digital asset volatility, regulatory uncertainty, and dependence on Rain protocol's success.

“risks relating to the Company’s operations and business, including the highly volatile nature of the price, trading volume, and liquidity of RAIN and other cryptocurrencies; risks associated with digital asset exchange listings, trading venues, and market infrastructure; the risk that the price and liquidity of the Company’s ordinary shares may be correlated” · word for word

Digital asset price volatility

“The fair value of the Company’s digital asset treasury as of December 31, 2025 was $606.781 million.” · word for word

Clinical trial failure

“We are currently preparing to commence a Phase IIb global, multicenter, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of intra-articular injections of Allocetra™ in age-related primary knee osteoarthritis.” · word for word

Regulatory uncertainty for digital assets

“The launch of central bank digital currencies (“CBDCs”) may adversely impact the value of our digital asset treasury.” · word for word

PFIC tax classification

“Our U.S. shareholders may suffer adverse tax consequences if we were to be characterized as a passive foreign investment company, or PFIC.” · word for word

Concentrated ownership

“Our principal shareholders, directors and officers currently own approximately 83.97% of our outstanding ordinary shares.” · word for word

Profitability driven by non-operational treasury asset appreciation, which may be volatile and non-recurring.

“Net income driven by appreciation in the valuation of the Company’s treasury and treasury-related derivative assets.”

Exposure to highly volatile digital assets (RAIN token) and prediction markets infrastructure.

“Treasury strategy centered on RAIN token, a decentralized prediction markets protocol.”

Note is secured by digital assets (RAIN tokens), which are highly volatile and could be subject to market downturns, increasing risk of default or forced liquidation.

“Company granted to the Investor a first priority security interest in certain of the Company’s accounts containing the Company’s digital assets, including its RAIN token portfolio.” · word for word

Potential dilution from conversion of note into ordinary shares at $2.69175 per share.

“The Note may be converted into Conversion Shares at an initial conversion price of $2.69175 per share.” · word for word

Clinical trial risk: Phase 2b trial may fail to meet endpoints, leading to negative outcomes.

“Phase 2b clinical trial designed to evaluate the efficacy and safety of intra-articular injections of Allocetra™.” · word for word

Dependence on volatile cryptocurrency market for treasury value; exchange listing does not eliminate price risk.

“RAIN token is the primary treasury asset; its value is subject to cryptocurrency market volatility.”

Dependence on volatile cryptocurrency market for treasury value; exchange listing does not eliminate price risk.

“RAIN token is the primary treasury asset; its value is subject to cryptocurrency market volatility.”

Loss of dual listing may reduce overall liquidity and investor base, particularly Israeli investors.

“Voluntary delisting from TASE; shares will trade exclusively on Nasdaq.”

Digital asset treasury strategy exposes company to cryptocurrency price volatility and liquidity risks.

“the highly volatile nature of the price, trading volume, and liquidity of RAIN and other cryptocurrencies” · word for word

Correlation risk between RAIN token liquidity and company's ordinary share liquidity.

“the risk that the price and liquidity of the Company's ordinary shares may be correlated with the price or liquidity of the digital assets it holds” · word for word

No revenue and ongoing operating losses; cash burn continues.

“Revenues $0 for all periods; operating loss $2.557M in Q3 2025.”